IDiyas

For the Inventor, By the Inventor

Berlin, Germany

Josef Heindl

USPTO Granted Patents = 20

Average Co-Inventor Count = 5.5

ph-index = 5

Forward Citations = 63(Granted Patents)


Company Filing History:

goldMedal19 out of 1,384 
 
Schering Aktiengesellschaft
 patents
silverMedal1 out of 1 
 
Schering Aktiengesellscaft
 patent

Years Active: 1988-2001

Loading Chart...
20 patents (USPTO):Explore Patents
1. 6271403 - 7&agr;-(xi-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7&agr;-(xi-aminoalkyl-estratrienes as well as their use for the production of pharmaceutical agents (2001-08-07),
2. 5986115 - 7.alpha.-(.xi.-aminoalkyl)-estratrienes, process for their production, (1999-11-16),
3. 5866560 - 7.alpha.-(.xi.-aminoalkyl)-estratrienes, process for their production, (1999-02-02),
4. 5859054 - Leukotriene B4 derivatives, process for their production and their use (1999-01-12),
5. 5783602 - Leukotriene-B4 derivatives, process for their production and their use (1998-07-21),
6. 5624943 - Pyridine compounds which are useful as leukotriene-B.sub.4 -antagonists (1997-04-29),
7. 5614634 - Leukotriene-B4 derivatives, process for their production and their use (1997-03-25),
8. 5559134 - Leukotriene-B.sub.4 antagonists, process for their production and their (1996-09-24),
9. 5541202 - New leukotriene-B4 Antagonists and their use as pharmaceutical agents (1996-07-30),
10. 5502075 - Leukotriene-B.sub.4 derivatives, process for their production and their (1996-03-26),
11. 5440044 - Leukotriene-B.sub.4 derivatives, process for their production and their (1995-08-08),
12. 5414016 - New leukotriene-B.sub.4 derivatives, process for their production and (1995-05-09),
13. 5352701 - Leukotriene-B.sub.4 antagonist compounds and their use as pharmaceutical (1994-10-04),
14. 5187286 - Leukotriene-B4 derivatives, process for their production and their use (1993-02-16),
15. 5183925 - Leukotriene-B4 derivatives, process for their production and their use (1993-02-02),

Title: Josef Heindl: A Pioneer in Pharmaceutical Innovations

Introduction

Josef Heindl is a distinguished inventor based in Berlin, Germany, known for his significant contributions to pharmaceutical innovations. With a remarkable portfolio of 20 patents, Heindl has made substantial advancements in the field of medicinal chemistry, particularly in antiestrogenic compounds.

Latest Patents

His latest patents focus on the development of 7α-(xi-aminoalkyl)-estratrienes, detailing a process for their production. These innovative pharmaceutical preparations include the mentioned estratrienes and their applications in manufacturing critical pharmaceutical agents. The inventions highlight new substituted 7α-(xi-aminoalkyl)-estratrienes characterized by a specific general formula, which are recognized for their strong antiestrogenic efficacy. The compounds can function as pure antiestrogens or possess partial estrogenic properties, making them highly effective for tumor therapy and hormone replacement treatment.

Career Highlights

Throughout his career, Josef Heindl has collaborated with prestigious organizations such as Schering Aktiengesellschaft, where he honed his expertise in pharmaceutical development. His work at Schering has positioned him as a key figure in the industry, paving the way for advancements in healthcare solutions.

Collaborations

Heindl has worked closely with notable coworkers such as Bernd Buchmann and Werner Skuballa. These collaborations have contributed to the successful development and realization of his innovative ideas within the pharmaceutical sector.

Conclusion

Josef Heindl's contributions to the field of pharmaceuticals through his inventive spirit and collaborative efforts have established him as an important figure in pharmaceutical chemistry. His patented innovations continue to influence therapeutic strategies, showcasing the profound impact of inventive minds in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…